I'll Drink to That

Now this is just cool.
If you like a nice glass of wine now and then, and like to support a good cause at the same time, then you've come to the right place. Check out www.onehope.com

Thye make wine. Good wine. Sometimes people find causes, other times causes find people, and such is the case with the eight founders of ONEHOPE. These young professionals have turned what started as a personal mission to help out a friend with her fight against cancer into a thriving business which is founded on a very basic, but compelling principle: giving back is good business.

ONEHOPE isn’t a charity, but a for-profit enterprise that donates 50% of profits to partner charities through the creation of cause specific varietals of wine.

There are wines for breast cancer, cancer, autism, AIDS, and our troops. There is a nice range of varieties available and surely you can find one that meets your palate and your conscience.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap